Precigen’s Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.
Why Is Precigen Stock Surging On Friday?
Where Today's News Shapes Tomorrow
November 10, 2026
Headlines
